ADCT

Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA plus rituximab achieved statistical significance on the trial's primary endpoint of progression-free survival (PFS) and demonstrated no detrimental effect on the key secondary efficacy endpoint of overall survival (OS). In addition, a higher complete response (CR) rate and duration of CRs (DoCR) were observed with ZYNLONTA plus rituximab. Overall, treatment emergent adverse event (TEAE) rates were similar between arms. Similar rates of overall Grade ≥3 TEAEs greater than 5% were observed across both arms, with hematologic TEAEs higher in the control arm and infection, hepatotoxicity, and edema/effusion higher in the test arm. Serious adverse events (SAEs), TEAEs leading to study drug withdrawal, and Grade 5 events were higher in the test arm, with the majority of Grade 5 TEAEs in the test arm occurring in patients aged 75 years or older. "In the context of a positive study, based on the totality of the data, we plan to discuss the benefit-risk profile of this combination with the U.S. FDA as we prepare for the planned supplemental Biologics License Application (sBLA) filing," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "We would like to extend our thanks to the patients, investigators, and clinical teams who contributed to this important trial." The LOTIS-5 trial is a randomized, open‐label, two‐arm, multicenter study evaluating ZYNLONTA plus rituximab versus the standard immunochemotherapy rituximab gemcitabine‐oxaliplatin (R‐GemOx), for the treatment of r/r DLBCL after one or more lines of systemic therapy. The study met the primary endpoint of PFS (per independent review committee) with statistical significance (HR = 0.73; p-value = 0.008 two sided), with a median PFS of 6.1 months for ZYNLONTA plus rituximab vs 4.7 months for R-GemOx. Overall survival showed no detrimental effect with ZYNLONTA plus rituximab compared to the control arm (HR = 0.96, impacted by the earlier use and a higher rate of new anti-lymphoma treatment switching in the control arm). Ov...

Management attributes the 15% year-over-year revenue growth primarily to normal customer ordering variability rather than a fundamental shift in market demand, which remains broadly stable. ZYNLONTA is positioned as a differentiated treatment for third-line plus DLBCL, characterized by rapid and durable efficacy with a manageable safety profile and convenient administration. The company is executing a life cycle management strategy to expand ZYNLONTA into earlier lines of therapy and indolent lymphomas, targeting peak U.S. annual revenues of $600 million to $1 billion. Operational efficiency improved through a 13% reduction in non-GAAP operating expenses, driven by lower R&D spending and disciplined capital allocation. Management believes the stability of product revenues over multiple quarters validates ZYNLONTA's established role in a highly competitive market environment. Strategic focus is shifting from research and development toward commercial manufacturing activities, reflected in the reallocation of certain personnel costs. Top-line data for the LOTIS-5 Phase III confirmatory trial is expected before the end of June 2026, which serves as the primary near-term value catalyst. Management anticipates an accelerated revenue growth trajectory starting in 2027, contingent upon positive clinical readouts and subsequent regulatory approvals. The company expects to submit a supplemental Biologics License Application (sBLA) for LOTIS-5 by year-end 2026, with potential compendia inclusion in the first half of 2027. Full data from the LOTIS-7 trial and various investigator-initiated trials in indolent lymphomas are anticipated between late 2026 and mid-2027. The current cash balance of $231 million is projected to support operations at least into 2028, providing a stable runway to reach upcoming clinical milestones. Cost of product sales increased due to a strategic shift in personnel allocation from R&D to commercial manufacturing, a trend expected to continue in future quarters. The company has entered a 'blackout period' regarding LOTIS-5 data, resulting in the cancellation of certain investor and analyst engagements until top-line results are disclosed. Future revenue projections for ZYNLONTA assume both successful regulatory approval and favorable compendia listing for new indications. Management noted that while recent revenue was strong, it is too early t...

Image source: The Motley Fool. Monday, May 4, 2026 at 8:30 a.m. ET Chief Executive Officer — Ameet Mallik Chief Financial Officer — Jose Carmona Head of Investor Relations — Nicole Riley Need a quote from a Motley Fool analyst? Email [email protected] Nicole Riley: Thank you, operator. Today, we issued a press release announcing our first quarter 2026 financial results and business updates. This release and the slides we will use in today's presentation are available on the Investors section of the ADC Therapeutics website. I'm joined on today's call by our Chief Executive Officer, Ameet Mallik, who will discuss our operational performance and recent business highlights, followed by our Chief Financial Officer, Pepe Carmona, who will review our first quarter 2026 financial results. We will then open the call to questions. Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain known and unknown risks and uncertainties, and actual results, performance and achievements could differ materially. They are identified and described in the accompanying slide presentation and in the company's filings with the SEC, including Form 10-K, 10-Q and 8-K. ADC Therapeutics is providing this information as of today's date and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events or circumstances, except as required by law. The company cautions investors not to place undue reliance on these forward-looking statements. Today's presentation also includes non-GAAP financial reporting. These non-GAAP measures should be considered in addition to and not in isolation or as a substitute for the information prepared in accordance with GAAP. You should refer to the company's first quarter 2026 earnings release for information and reconciliation of historical non-GAAP measures to the comparable GAAP financial measures. I will now turn the call over to our CEO, Ameet Mallik. Ameet? Ameet Mallik: Thank you, Nicole. We continue to make good progress in the first quarter of 2026 as we advance towards multiple important milestones for ZYNLON...

Image source: The Motley Fool. Tuesday, March 10, 2026, at 8:30 a.m. ET Chief Executive Officer — Ameet Mallik Chief Financial Officer — Jose Carmona Need a quote from a Motley Fool analyst? Email [email protected] Ameet Mallik, who will discuss our operational performance and recent business highlights, followed by our Chief Financial Officer, Pepe Carmona, who will review our fourth quarter and full year 2025 financial results. We will then open the call to questions. Before we begin, I would like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain known and unknown risks and uncertainties and actual results, performance and achievements could differ materially. They are identified and described in the accompanying slide presentation and in the company's filings with the SEC, including Form 10-K, 10-Q and 8-K. ADC Therapeutics is providing this information as of today's date and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events or circumstances, except as required by law. The company cautions investors not to place undue reliance on these forward-looking statements. Today's presentation also includes non-GAAP financial reporting. These non-GAAP measures should be considered in addition to and not in isolation or as a substitute for the information prepared in accordance with GAAP. You should refer to the company's fourth quarter full year 2025 earnings release for information and reconciliations of historical non-GAAP measures to the comparable GAAP financial measures. I will now turn the call over to our CEO, Ameet Mallik. Ameet? Ameet Mallik: Thanks, Nicole, and hello, everyone. Thank you for joining us on today's call. We are pleased to share an update on our achievements in 2025 and our excitement for the future. Before I get into the details, I'd like to take a moment to reflect on the progress we've made over the past few years and why we believe this positions us strongly for the future. We have implemented a strategic plan to focus on ZYNLONTA with optimized life cycle management. This includes advancing LOTIS-5 as well...

ADC reported Q1 2026 net product revenue for ZYNLONTA of $20.0 million (up from $17.4M a year ago), which management said mainly reflects quarter-to-quarter ordering variability with underlying demand broadly stable. The company expects top-line results from the Phase 3 LOTIS-5 trial before the end of June while remaining blinded; the release should include PFS, hazard ratio, key secondary endpoints and safety, and ADC plans an sBLA submission by year-end 2026 if positive but does not expect a 2026 revenue impact from the readout. Non-GAAP adjusted operating expenses fell to $42.9 million (down 13% YoY), GAAP net loss narrowed to $33.0 million, and the company ended the quarter with $231 million in cash, which management says supports a runway at least into 2028. Interested in ADC Therapeutics SA? Here are five stocks we like better. ADC Therapeutics (NYSE:ADCT) reported first-quarter 2026 net product revenue growth for its lymphoma therapy ZYNLONTA and reiterated expectations for multiple upcoming clinical milestones, led by a near-term top-line readout from its Phase 3 LOTIS-5 trial. Chief Executive Officer Ameet Mallik said the company’s commercial focus remains on “execution” and maintaining ZYNLONTA as a “differentiated treatment option for third-line plus DLBCL patients.” First-quarter 2026 net product revenues were $20.0 million, compared with $17.4 million in the prior-year quarter. → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook Mallik attributed the increase primarily to “normal quarter-to-quarter variability in customer ordering,” adding that “underlying demand [is] broadly stable.” During the Q&A session, management also emphasized caution about interpreting a single quarter as a trend. Addressing the quarterly cadence, the company referenced prior quarter variability, including a lower third quarter and stronger fourth quarter in 2025, and said it was “too soon to call a change in trend.” Mallik said ADC Therapeutics believes “the relative stability we’ve seen in net product revenues over multiple quarters demonstrates that ZYNLONTA has a clear place in this market,” while describing expansion into earlier lines of therapy and indolent lymphomas as future growth opportunities. → The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches Management highlighted LOTIS-5, a Phase 3 confirmatory trial evaluating ZYNLO...

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates. "During the first quarter, we continued to build momentum across our ZYNLONTA program," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "Looking ahead, we have multiple near-term catalysts, including topline results from LOTIS-5 anticipated in the second quarter, full results expected from both LOTIS-5 and LOTIS-7 by year-end, as well as additional updates from the investigator-initiated studies in indolent lymphomas ahead. We believe that we are well-positioned to expand ZYNLONTA's role across B-cell malignancies, accelerating our expected growth trajectory starting in 2027." First Quarter 2026 Operational Updates and Upcoming Milestones LOTIS-5 topline results anticipated in 2Q 2026. The Company continues to expect to announce topline results from the LOTIS-5 Phase 3 confirmatory trial of ZYNLONTAﾮ (loncastuximab tesirine-lpyl) in combination with rituximab in the second quarter of 2026, with full results anticipated by year-end. If positive, the Company intends to submit a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) before year-end, with potential compendia inclusion in the first half of 2027 and confirmatory approval in 2L+ diffuse large B-cell lymphoma (DLBCL) thereafter. LOTIS-7 trial ongoing with data anticipated by year-end. The LOTIS-7 Phase 1b trial evaluating ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVIﾮ) in patients with relapsed or refractory (r/r) DLBCL is ongoing, with expected completion of enrollment at the selected 150 ﾵg/kg dose in the first half of 2026. The Company plans to share full data at a medical meeting and through publication by the end of 2026. The Company also intends to evaluate potential regulato...

This article first appeared on GuruFocus. ADC Therapeutics SA (NYSE:ADCT) is set to release its Q1 2026 earnings on May 4, 2026. The consensus estimate for Q1 2026 revenue is $19.24 million, and the earnings are expected to come in at -$0.24 per share. The full year 2026's revenue is expected to be $76.64 million, and the earnings are expected to be -$0.94 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 4 Warning Signs with ADCT. Is ADCT fairly valued? Test your thesis with our free DCF calculator. Revenue estimates for ADC Therapeutics SA (NYSE:ADCT) have declined from $80.63 million to $76.64 million for the full year 2026 and from $148.88 million to $129.61 million for 2027 over the past 90 days. Earnings estimates have increased from -$1.08 per share to -$0.94 per share for the full year 2026, while they have declined from -$0.68 per share to -$0.76 per share for 2027 over the past 90 days. In the previous quarter of 2025-12-31, ADC Therapeutics SA's (NYSE:ADCT) actual revenue was $23.06 million, which beat analysts' revenue expectations of $21.39 million by 7.80%. ADC Therapeutics SA's (NYSE:ADCT) actual earnings were -$0.04 per share, which beat analysts' earnings expectations of -$0.27 per share by 85.35%. After releasing the results, ADC Therapeutics SA (NYSE:ADCT) was up by 13.48% in one day. Based on the one-year price targets offered by 5 analysts, the average target price for ADC Therapeutics SA (NYSE:ADCT) is $8.20, with a high estimate of $10.00 and a low estimate of $6.00. The average target implies an upside of 116.93% from the current price of $3.78. Based on GuruFocus estimates, the estimated GF Value for ADC Therapeutics SA (NYSE:ADCT) in one year is $1.55, suggesting a downside of -58.99% from the current price of $3.78. Based on the consensus recommendation from 6 brokerage firms, ADC Therapeutics SA's (NYSE:ADCT) average brokerage recommendation is currently 1.5, indicating a "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.

LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTAﾮ (loncastuximab tesirine-lpyl). ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Headquartered in Lausanne (Biop￴le), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain ri...

This article first appeared on GuruFocus. Q4 2025 Net Product Revenue: $22.3 million, up from $16.4 million in Q4 2024. Full-Year 2025 Net Product Revenue: $73.6 million, compared to $69.3 million in 2024. Q4 2025 Total Operating Expenses: $41 million. Full-Year 2025 Total Operating Expenses: $202.9 million. Q4 2025 Non-GAAP Adjusted Operating Expenses: $39.4 million. Full-Year 2025 Non-GAAP Adjusted Operating Expenses: $181.3 million. Q4 2025 Net Loss: $6.4 million or $0.04 per share, compared to $30.7 million or $0.29 per share in Q4 2024. Full-Year 2025 Net Loss: $142.6 million or $1.12 per share, compared to $157.8 million or $1.62 per share in 2024. Cash and Cash Equivalents at Year-End 2025: $261.3 million, up from $250.9 million at the end of 2024. Warning! GuruFocus has detected 6 Warning Signs with ADCT. Is ADCT fairly valued? Test your thesis with our free DCF calculator. Release Date: March 10, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. ADC Therapeutics SA (NYSE:ADCT) successfully reduced its operating cost structure by approximately 50%, enhancing financial efficiency. The company reported strong Q4 2025 net product revenues of $22.3 million, a significant increase from $16.4 million in Q4 2024. ADCT strengthened its balance sheet with a cash balance of $261 million, providing a cash runway expected to last into 2028. The company achieved a 10% market share in the third-line plus setting for ZYNLONTA as a monotherapy, demonstrating its competitive positioning. ADCT anticipates potential peak annual US revenue of $600 million to $1 billion for ZYNLONTA, assuming regulatory approval and compendia inclusion. Despite progress, ADCT's net loss for the full year 2025 was $142.6 million, indicating ongoing financial challenges. The company faces a competitive market landscape with the entry of bispecific therapies, which could impact ZYNLONTA's market share. ADCT's revenue growth is currently limited, with 2025 sales remaining roughly stable compared to 2024. The company is reliant on successful clinical trial outcomes and regulatory approvals to achieve its projected revenue growth. ADCT's future growth is contingent on expanding ZYNLONTA's use into earlier lines of therapy, which involves significant strategic and operational risks. Q: At a high level, how are PFS events tracking relative...

LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent operational updates. "Building off the meaningful progress achieved across our ZYNLONTA clinical program in DLBCL and through investigator-initiated trials in indolent lymphomas this past year, we believe we have laid the foundation for multiple anticipated value-creating catalysts," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "We expect topline LOTIS-5 results in the second quarter, followed by full LOTIS-5 and LOTIS-7 results in 2L+ DLBCL by the end of 2026 and, assuming positive data, potential compendia inclusions in first half of 2027 with LOTIS-5 regulatory approval to follow. Supported by an expected cash runway at least into 2028, we are confident we will drive significant potential long-term growth beginning in 2027." Fourth Quarter 2025 Operational Updates and Upcoming Milestones LOTIS-5 topline results anticipated in 2Q 2026. The Company expects to provide topline data in 2Q 2026 from the LOTIS-5 Phase 3 confirmatory trial of ZYNLONTAﾮ (loncastuximab tesirine-lpyl) in combination with rituximab in patients with 2L+ diffuse large B-cell lymphoma (DLBCL) once the pre-specified number of approximately 262 progression-free survival events is reached and data are available. Full results are anticipated to be published by the end of 2026. Assuming positive results, the Company will file a supplemental Biologics License Application (sBLA) submission with the U.S. Food and Drug Administration (FDA), with potential compendia inclusion in the first half of 2027 and confirmatory approval in 2L+ DLBCL to follow in mid-2027. LOTIS-7 trial ongoing with data anticipated b...

ADC has refocused on ZYNLONTA with an optimized lifecycle plan and ~50% reduction in operating costs, while bolstering the balance sheet via $100M and $60M PIPE financings to support a cash runway into at least 2028. Major clinical catalysts include LOTIS-5 top-line data expected in Q2 2026 (PFS primary endpoint) with a potential supplemental BLA/approval pathway in 2027, and LOTIS-7 showing strong early efficacy (90% BOR, 78% CR) with expanded enrollment. Commercial and financials were roughly stable: Q4 net product revenue was $22.3 million and full-year net product revenue was $73.6 million, while Q4 GAAP net loss improved to $6.4 million and adjusted operating expenses declined year-over-year. Interested in ADC Therapeutics SA? Here are five stocks we like better. ADC Therapeutics (NYSE:ADCT) outlined a 2025 strategy centered on expanding ZYNLONTA while significantly reducing costs, and management pointed investors to multiple clinical and regulatory catalysts expected in 2026 and 2027. Chief Executive Officer Ameet Mallik said the company has implemented a plan to focus on ZYNLONTA “with optimized lifecycle management,” including the Phase III LOTIS-5 study, the bispecific combination study LOTIS-7, and investigator-initiated trials (IITs) in indolent lymphomas. Mallik said ADC Therapeutics reduced its operating cost structure by approximately 50% as part of this focus and restructuring, while refining its go-to-market model to maintain a sustained position for ZYNLONTA in third-line-plus diffuse large B-cell lymphoma (DLBCL) despite the entry of bispecific therapies. → Microsoft Positioned to Win AI Race With Dual-Model Strategy Mallik also highlighted balance sheet actions, including equity financing and business development activity, and said an amended agreement with HealthCare Royalty improved strategic flexibility. He framed the company’s value-creation priorities around three “horizons”: final data disclosures, approval and compendia inclusion, and ultimately delivering growth. Management said ZYNLONTA maintained its place in the third-line-plus DLBCL setting. Mallik noted that after an unusually low third quarter, fourth-quarter performance was strong. Net product revenue in Q4 2025 was $22.3 million, which he attributed primarily to variability in customer ordering patterns and activation of some new accounts. → Why This Defense ETF Could Keep...